The Vocabulary of How Drugs Work
Pharmacology has its own precise vocabulary for describing what a drug actually does once it enters the body, and much of that vocabulary is organized around a simple acronym: ADME, for absorption, distribution, metabolism, and excretion. Absorption describes how a drug enters the bloodstream from wherever it was administered; distribution describes how it then spreads from the blood into body tissues; metabolism describes how the body chemically transforms it, mostly in the liver; and excretion describes how it and its byproducts eventually leave the body, mostly through the kidneys. Related terms build directly on this framework: bioavailability measures what proportion of a drug actually reaches the bloodstream in an active form, half-life measures how long it takes for the drug's concentration in the body to drop by half, and the "first-pass effect" describes how a drug taken by mouth loses potency after an initial trip through the liver, before ever reaching general circulation.
A separate branch of pharmacology vocabulary, pharmacodynamics, describes not where a drug goes but what it does once it gets there — specifically, how it interacts with receptors, the protein structures on cells that a drug binds to in order to produce an effect. An agonist binds to a receptor and activates it, producing a response. An antagonist binds to the same kind of receptor without activating it, blocking other substances from doing so. A partial agonist sits in between: it activates the receptor, but produces a smaller maximum effect than a full agonist ever could. These three terms describe a genuine spectrum of receptor behavior, not just a vocabulary list, and confusing them means describing a completely different mechanism of action.
From Paracelsus to the FDA
Long before pharmacology existed as a formal science, a 16th-century Swiss physician named Paracelsus articulated a principle still quoted at the center of toxicology today: "Sola dosis facit venenum" — "only the dose makes the poison." The idea that literally any substance can be harmful or harmless purely depending on the amount involved was a genuine conceptual leap for its era, and it remains the foundation of how modern pharmacology thinks about drug safety. Centuries later, German scientist Paul Ehrlich extended this line of thinking toward treatment itself with his "magic bullet" concept: the idea that a drug could be designed to target disease-causing organisms specifically, without harming the patient carrying them. Ehrlich's own 1910 development of Salvarsan, one of the first effective targeted drug treatments in history, was a direct application of that idea, decades before "targeted therapy" became a familiar phrase.
Government regulation of drugs is a much more recent story. The Pure Food and Drug Act of 1906 was the first major U.S. federal law addressing food and drug safety, passed partly in response to public outcry over unsafe practices exposed in investigative writing of the era. Its enforcement responsibilities eventually evolved into what became, by 1930, the U.S. Food and Drug Administration. That same regulatory tradition produced the naming systems that keep today's drugs straight: a drug's generic name is its official, non-brand identity, assigned in the United States through the USAN system and coordinated internationally through the World Health Organization's INN system, established in 1953 specifically so a single drug wouldn't end up with a different official name in every country that used it. Even the Controlled Substances Act of 1970, which created the five-tier Schedule I through Schedule V classification system still used today, was built on the same underlying logic Paracelsus described five centuries earlier — that a substance's risk depends on how, and how much, it's actually used.
Source: National Institutes of Health (NIH) and Encyclopaedia Britannica.